IceCure Regains Compliance with Nasdaq Minimum Bid Price Requirement

IceCure (NASDAQ: ICCM) announced it has regained compliance with Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2), which requires a bid price of at least $1.00 per share.

Rhea-AI Summary

IceCure (NASDAQ: ICCM) announced it has regained compliance with Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2), which requires a bid price of at least $1.00 per share.

Nasdaq determined compliance after ICCM's closing bid met or exceeded $1.00 for 10 consecutive business days from June 4–17, 2026, and considers the bid price deficiency matter closed.

Positive

• Nasdaq confirms ICCM regained compliance with $1.00 minimum bid rule
• Closing bid at or above $1.00 for 10 consecutive business days
• Nasdaq considers prior bid price deficiency matter closed

Negative

• None.

Argus Jun 25 session

-24.52% close to close Open Argus

Details

News Market Reaction – ICCM

In the Jun 25 session, ICCM declined 24.52%, reflecting a significant negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock dropped -24.5% in the session following this news. A negative reaction despite positive co...

Analysis

The stock dropped -24.5% in the session following this news. A negative reaction despite positive compliance news fits a pattern where capital-structure concerns, dilution capacity from the active shelf, or heavy short positioning overshadow listing milestones and leave shares sensitive to shifts in financing or liquidity expectations.

Key Figures

Nasdaq minimum bid: $1.00 per share Compliance streak: 10 consecutive business days Compliance notice date: June 18, 2026

Nasdaq minimum bid

$1.00 per share

Required minimum bid price under Nasdaq Listing Rule 5550(a)(2)

Compliance streak

10 consecutive business days

Closing bid at or above $1.00 from Jun 4–17, 2026

Compliance notice date

June 18, 2026

Date Nasdaq notified IceCure of regaining bid price compliance

Historical Context

5 past events · Latest: Jun 23

5 events

1. Jun 23

   Clinical data update

   24h Move

   +3.2%

   Peer-reviewed article showing ProSense cryoablation advantages in early-stage breast cancer.

2. Jun 17

   Private placement financing

   24h Move

   +200.5%

   Premium-priced $5.5M private placement with single healthcare-focused institutional investor.

3. Jun 17

   Install base growth

   24h Move

   +200.5%

   Reported 70% growth in active U.S. commercial ProSense install base after FDA clearance.

4. Jun 02

   Reverse share split

   24h Move

   -30.9%

   1-for-30 reverse split implemented to support Nasdaq $1.00 minimum bid compliance.

5. May 19

   Clinical conference data

   24h Move

   +3.6%

   ICESECRET kidney and breast cryoablation outcomes presented at ECIO 2026 conference.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

cryoablation, minimum bid price

2 terms

cryoablation medical

"developer of minimally-invasive cryoablation technology that destroys tumors by freezing"

A medical treatment that uses extreme cold to freeze and destroy unwanted tissue, such as small tumors or heart tissue causing irregular rhythms; think of it like applying a focused freezer to stop a problem spot without cutting it out. It matters to investors because devices, tools, and drugs tied to cryoablation, plus clinical results, approval status and insurance coverage, can drive sales, shape market adoption and affect the financial outlook of healthcare companies.

minimum bid price regulatory

"regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2)"

The minimum bid price is the lowest share price that a market, regulator, or specific offering will accept for a trade, listing, or auction—think of it as a reserve or floor that a stock must meet to qualify for certain actions. It matters to investors because falling below that floor can limit trading options, trigger compliance measures or delisting risks, and affect liquidity and the perceived value of a holding, much like a reserve price in an auction sets the baseline for a sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAESAREA, Israel, June 25, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that on June 18, 2026, it received written notice from Nasdaq Stock Market LLC ("Nasdaq"), indicating that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share.

The Nasdaq staff made this determination of compliance after the closing bid price of the Company's ordinary shares was $1.00 per share or greater for the 10 consecutive business days from June 4 to June 17, 2026. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and Nasdaq considers the bid price deficiency matter now closed.

About IceCure Medical

IceCure Medical (NASDAQ: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe and Asia.

IR Contact:

Email: investors@icecure-medical.com
Meir Peleg, CFO
Phone: +1-888-902-5716 

Logo: https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg

 

View original content:https://www.prnewswire.com/news-releases/icecure-regains-compliance-with-nasdaq-minimum-bid-price-requirement-302810665.html

SOURCE IceCure Medical

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did IceCure (NASDAQ: ICCM) announce about Nasdaq compliance on June 25, 2026?

IceCure announced it has regained compliance with Nasdaq’s minimum bid price requirement. According to IceCure, Nasdaq confirmed the company met the $1.00 per share threshold for 10 consecutive business days, and the prior bid price deficiency matter is now closed.

How did IceCure (ICCM) regain compliance with Nasdaq Listing Rule 5550(a)(2)?

IceCure regained compliance by maintaining a closing bid price of at least $1.00 per share. According to IceCure, its ordinary shares closed at or above $1.00 for 10 consecutive business days from June 4 through June 17, 2026.

What is Nasdaq Listing Rule 5550(a)(2) and how does it affect IceCure (ICCM)?

Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share. According to IceCure, its ordinary shares now satisfy this requirement again after trading at or above $1.00 for 10 consecutive business days.

On what dates did IceCure’s (ICCM) share price meet Nasdaq’s $1.00 minimum bid requirement?

IceCure met Nasdaq’s $1.00 minimum bid requirement over a 10-business-day period. According to IceCure, its ordinary shares closed at $1.00 per share or greater from June 4 to June 17, 2026, leading Nasdaq to confirm renewed compliance.

Is the Nasdaq bid price deficiency issue for IceCure (ICCM) now resolved?

Yes, Nasdaq considers the prior bid price deficiency matter closed for IceCure. According to IceCure, after its shares traded at or above a $1.00 closing bid for 10 consecutive business days, Nasdaq confirmed compliance with Listing Rule 5550(a)(2).

What does regaining Nasdaq minimum bid price compliance mean for IceCure (ICCM) shareholders?

Regaining compliance means IceCure currently meets Nasdaq’s minimum $1.00 bid price requirement. According to IceCure, Nasdaq confirmed its shares closed at or above $1.00 for 10 straight business days, and the exchange now treats the bid price deficiency matter as closed.